Drugging the Undruggable: New Acquisition to Boost GPCR Drugs
Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its…
November 30, 2016 - 2 minutes
Psychiatric disorders
World Mental Health Day: How is Biotech Helping the Cause?
Biotech is one of the main forces driving the development of effective therapies to treat neurological and…
October 11, 2016 - 4 minutes
New Biomarkers could make Personalized Medicine for Depression
Researchers from King’s College London have succeeded in developing a blood test that can help choose…
June 14, 2016 - 3 minutes
Sorry Scotland, Phase II Trial for Clinical Depression Fails against 55-Year Old Generic
I mean, Clinical depression is a tough indication for Biotech to tackle - particularly when facing…
February 16, 2016 - 3 minutes
Epigenetics Baby of Proteros is Signing Up with Top US Neurology Specialists
Founded in just 2013 by German Proteros and the US Atlas Ventures, Rodin Therapeutics is…
January 8, 2016 - 3 minutes
Growing Mini-Brains in Labs to Better Understand Neurological Disease
Mini brains, about 3-4 mm are a breakthrough in Neurology which will enable researchers to…
January 6, 2016 - 2 minutes
Succesful Phase III for Indivior’s Schizophrenia treatment
Indivior obtained top-line results from its phase III clinical trial of RBP-7000, a candidate treatment…
May 10, 2015 - 1 minute
Newron raised new funds to continue the development of Neurological therapies
Newron Pharmaceuticals, a public company focused on novel Central Nervous System (CNS) and pain therapies, announces…
May 2, 2015 - 2 minutes
AOP Orphan and Confluence Pharmaceuticals, together for Fragile X Syndrome
AOP Orphan Pharmaceuticals and Confluence Pharmaceuticals, signed today a definitive agreement to co-develop and market…
March 23, 2015 - 2 minutes
Alkermes presents its new treatment of Alzheimer’s agitation
Alkermes reveals a new drug candidate, ALKS 7119, for treatment of Alzheimer’s agitation, depression and…
March 4, 2015 - 2 minutes
